|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NPEPL1 |
Gene summary for NPEPL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NPEPL1 | Gene ID | 79716 |
| Gene name | aminopeptidase like 1 | |
| Gene Alias | bA261P9.2 | |
| Cytomap | 20q13.32 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q8NDH3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79716 | NPEPL1 | LZE4T | Human | Esophagus | ESCC | 4.85e-06 | 2.28e-01 | 0.0811 |
| 79716 | NPEPL1 | LZE7T | Human | Esophagus | ESCC | 1.20e-06 | 2.58e-01 | 0.0667 |
| 79716 | NPEPL1 | LZE20T | Human | Esophagus | ESCC | 6.39e-07 | 3.28e-01 | 0.0662 |
| 79716 | NPEPL1 | LZE22D1 | Human | Esophagus | HGIN | 8.85e-04 | 1.58e-01 | 0.0595 |
| 79716 | NPEPL1 | LZE24T | Human | Esophagus | ESCC | 2.30e-02 | 1.21e-01 | 0.0596 |
| 79716 | NPEPL1 | P1T-E | Human | Esophagus | ESCC | 4.76e-10 | 3.72e-01 | 0.0875 |
| 79716 | NPEPL1 | P2T-E | Human | Esophagus | ESCC | 1.52e-13 | 1.68e-01 | 0.1177 |
| 79716 | NPEPL1 | P4T-E | Human | Esophagus | ESCC | 1.96e-02 | 5.88e-02 | 0.1323 |
| 79716 | NPEPL1 | P5T-E | Human | Esophagus | ESCC | 3.40e-07 | 9.05e-02 | 0.1327 |
| 79716 | NPEPL1 | P8T-E | Human | Esophagus | ESCC | 8.08e-09 | 1.10e-01 | 0.0889 |
| 79716 | NPEPL1 | P9T-E | Human | Esophagus | ESCC | 1.48e-08 | 1.46e-01 | 0.1131 |
| 79716 | NPEPL1 | P10T-E | Human | Esophagus | ESCC | 2.32e-17 | 2.46e-01 | 0.116 |
| 79716 | NPEPL1 | P11T-E | Human | Esophagus | ESCC | 5.40e-10 | 3.59e-01 | 0.1426 |
| 79716 | NPEPL1 | P12T-E | Human | Esophagus | ESCC | 8.60e-16 | 3.91e-01 | 0.1122 |
| 79716 | NPEPL1 | P15T-E | Human | Esophagus | ESCC | 4.03e-19 | 3.28e-01 | 0.1149 |
| 79716 | NPEPL1 | P19T-E | Human | Esophagus | ESCC | 8.64e-08 | 4.48e-01 | 0.1662 |
| 79716 | NPEPL1 | P20T-E | Human | Esophagus | ESCC | 5.00e-29 | 5.65e-01 | 0.1124 |
| 79716 | NPEPL1 | P21T-E | Human | Esophagus | ESCC | 1.26e-11 | 1.83e-01 | 0.1617 |
| 79716 | NPEPL1 | P22T-E | Human | Esophagus | ESCC | 9.22e-18 | 2.14e-01 | 0.1236 |
| 79716 | NPEPL1 | P23T-E | Human | Esophagus | ESCC | 2.43e-22 | 5.06e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NPEPL1 | SNV | Missense_Mutation | c.809G>A | p.Ser270Asn | p.S270N | Q8NDH3 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NPEPL1 | deletion | Frame_Shift_Del | novel | c.694delN | p.Gly232AlafsTer49 | p.G232Afs*49 | Q8NDH3 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| NPEPL1 | SNV | Missense_Mutation | c.178A>G | p.Asn60Asp | p.N60D | Q8NDH3 | protein_coding | tolerated(0.2) | benign(0.007) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | |
| NPEPL1 | SNV | Missense_Mutation | rs764057579 | c.269N>T | p.Ser90Leu | p.S90L | Q8NDH3 | protein_coding | deleterious(0) | benign(0.105) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| NPEPL1 | SNV | Missense_Mutation | novel | c.940G>C | p.Glu314Gln | p.E314Q | Q8NDH3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-AA62-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| NPEPL1 | SNV | Missense_Mutation | c.1314N>G | p.Asn438Lys | p.N438K | Q8NDH3 | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NPEPL1 | SNV | Missense_Mutation | rs758011690 | c.287N>T | p.Thr96Met | p.T96M | Q8NDH3 | protein_coding | deleterious(0.05) | possibly_damaging(0.776) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| NPEPL1 | SNV | Missense_Mutation | rs777053585 | c.409N>T | p.Arg137Cys | p.R137C | Q8NDH3 | protein_coding | deleterious(0) | possibly_damaging(0.856) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| NPEPL1 | SNV | Missense_Mutation | c.229N>A | p.Ala77Thr | p.A77T | Q8NDH3 | protein_coding | deleterious(0.02) | possibly_damaging(0.492) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NPEPL1 | SNV | Missense_Mutation | rs201082731 | c.650N>T | p.Asp217Val | p.D217V | Q8NDH3 | protein_coding | deleterious(0) | benign(0.251) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 79716 | NPEPL1 | PROTEASE, ENZYME | inhibitor | CHEMBL2103847 | TOSEDOSTAT |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |